The Clinical BioManufacturing Facility (CBF) at the University of Oxford is a leading GMP-certified facility specialising in the production of biological Investigational Medicinal Products (IMPs) for early-phase clinical trials.

With over 20 years of experience, CBF bridges the gap between academic research and clinical drug development. It supports both academic and commercial sectors, providing advanced manufacturing capabilities for novel biotech products. The facility offers a full range of services, from viral vector and recombinant protein vaccines to cell and gene therapy products.

Key Products and Services

• GMP manufacturing for early-phase clinical trials
• Viral vector and recombinant protein vaccines
• Advanced Therapy Medicinal Products (ATMPs) including cell and gene therapies
• Manufacturer’s Authorisation for Investigational Medicinal Products (MIA)
• Importation of IMPs for use in EU clinical trials

CBF’s high-quality, efficient manufacturing solutions continue to support the rapid progression of innovative treatments, ensuring significant benefits to patients globally.